The word sepsis was derived from the Greek word: sêpsis, which means the state of putrefaction or decay. Sepsis is a potentially deadly medical condition that is characterized by a whole-body inflammatory state, called a systemic inflammatory response syndrome, and the presence of a known or suspected infection. The more critical subsets of sepsis are severe sepsis with acute organ dysfunction, hypoperfusion, or hypotension and septic shock with refractory arterial hypotension despite adequate fluid resuscitation [1, 2]. Because the molecular pathogenesis of sepsis is incompletely understood and its specific and effective therapies are lacking, sepsis is still a major cause of death in intensive-care units worldwide, with mortality rates that range from 20% for sepsis, through 40% for severe sepsis, to over 60% for septic shock [3, 4]. More knowledge of the pathophysiology of sepsis is needed if we are to develop better, more effective interventions to sepsis. It has been increasingly recognized that genetic factors influence individual susceptibility, severity and outcome in sepsis [5, 6]. Identification of new genetic factors in sepsis may hold promise for new mechanistic insights and new therapeutic modalities.
Nicotinamide phosphoribosyltransferase (NAMPT) is emerging as a risk factor in sepsis. NAMPT is a pleiotropic protein. It catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, which is the key step in a salvage pathway of the mammalian NAD biosynthesis. NAMPT was first cloned by Samal et al.and it was originally named pre-B-cell colony enhancing factor (PBEF) because it can promote the maturation of pre-B-cells. NAMPT was also called visfatin because it is an adipokine highly produced by visceral fat and it displayed insulin mimetic functions  though the latter claim was disputed in literature. In this chapter, NAMPT and PBEF are used interchangeably in some parts. Jia et al.  from University of Toronto, Canada, first reported that NAMPT mRNA in neutrophils from critically ill septic patients was expressed at higher levels than those in controls. Our previous study at Johns Hopkins University, USA, discovered that a susceptible haplotype GC in the promoter of human NAMPT gene had a 4.84-fold higher risk of sepsis while a potential protective haplotype TT had a lower risk of sepsis in a Caucasian patient population . Bajwa et al.  from Massachusetts General Hospital, Harvard University, USA, replicated and extended our findings that the NAMPT-1001T>G variant allele and related haplotype were associated with increased odds of developing acute respiratory distress syndrome (ARDS), which is frequently associated with severe sepsis, and increased hazard of intensive care unit mortality among at-risk patients, whereas the -1535C>T (originally labeled as -1543C>T) variant allele and related haplotype are associated with decreased odds of ARDS among patients with septic shock and better outcomes among patients with ARDS. Molecular mechanisms underlying these associations have been actively explored. The first part of this chapter introduces the physiological functions of the NAMPT gene. The second part of this chapter synopsize the clinical investigation and epidemiological studies of NAMPT in sepsis. The third part describes our current understanding of molecular mechanisms underlying NAMPT in sepsis. The final part of this chapter includes a brief summary and some perspectives on exploring
2. Physiological functions of the NAMPT gene
This section briefly introduces the three major functions of the NAMPT: Growth Factor, Cytokine and Nicotinamide phosphoribosyltransferase . Accumulating evidence suggests that NAMPT can function as a growth factor or a cytokine though the underlying molecular mechanisms remain to be established. It is beyond the dispute that NAMPT can function as a Nicotinamide phosphoribosyltransferase.
Because the salvage pathway of NAD synthesis is much more efficient and quicker one than that of de novo NAD synthesis, it is conceivable that NAMPT plays an important role in varieties of physiological processes in life via the synthesis of NAD. NAD is now regarded as a universal energy- and signal-carrying molecule[28, 29]. Recent research has unraveled an unexpectedly wide array of signaling pathways that involve nicotinamide adenine dinucleotide (NAD) and its phosphorylated form, NADP. NAD serves as substrate for protein modification including protein deacetylation and mono- and poly-ADP-ribosylation. Both NAD and NADP represent precursors of intracellular calcium-mobilizing molecules. It is now well accepted that NAD (P)-mediated signal transduction does not merely regulate metabolic pathways but might hold a key position in the control of fundamental cellular processes. In mammals, it has been shown recently that an NAD-dependent protein deacetylase, silent information regulator (SIR) T1/2, plays important roles in a variety of biological processes, such as stress and cytokine responses, by deacetylating transcriptional regulators. Endogenous mono-ADP-ribosylation in higher eukaryotes appears to modulate the immune response, cell adhesion, signal, and energy metabolism. Recently, defensin-1, an antimicrobial arginine-rich protein secreted by immune cells, was demonstrated to lose its antimicrobial effect after its mono-ADP-ribosylation. Poly-ADP-ribosylation of proteins such as NFkB by poly-ADP-ribose polymerase can trigger the release of apoptosis-inducing factor from mitochondria and therefore effectively mediate apoptosis. Gerth et al. demonstrated that NAD and ADP-ribose, generated from NAD by CD38, an NAD-glycohydrolase, induce the activation of a Ca2+ channel through a pathway that involves Ca2+ influx in human monocytes. Ca2+ ions play a critical role in variety of monocyte functions such as chemotaxis and production of cytokine (TNF). Increased intracellular calcium in human monocyte-derived macrophages
3. Role of NAMPT in Sepsis
Because of its pleiotropic functions, NAMPT has been implicated in various human diseases including sepsis.Increasing evidence indicates that NAMPT is a risk factor in sepsis. Jia et al.  determined the expression of PBEF in neutrophils harvested from 16 critically ill septic patients in an intensive care unit. They found that neutrophils from these patients showed marked expression of PBEF mRNA. PBEF expression was significantly greater in neutrophils from septic patients than in resting neutrophils or LPS-stimulated neutrophils from healthy volunteers. Lee et al.  determined the clinical correlates for elevated plasma PBEF upon intensive care unit admission for severe sepsis and the usefulness of NAMPT to predict sepsis mortality.Plasma collected within 24 h of intensive care unit admission was measured for NAMPT concentrations by enzyme-linked immunosorbent assay. They reported that elevated PBEF levels significantly correlated with higher Acute Physiology and Chronic Health Evaluation III scores (R(2) = 0.08, P =.003). The higher Acute Physiology and Chronic Health Evaluation III score indicates more severe diseased status. Non-survivors had higher PBEF levels than survivors (2.53 ng/mL; interquartile range [IQR], 1.07-8.16 vs 1.44 ng/mL; IQR, 0.84-2.81; P =.02). They concluded that NAMPT was associated with sepsis mortality mainly due to its association with greater severity of illness on intensive care unit admission.Cekmez et al.  found that plasma NAMPT level was significantly higher in septic infants than in healthy ones. There was a positive correlation between NAMPT and other markers (white blood cells,
In our previous genetic epidemiological study , we determined the frequencies of minor alleles, genotypes and haplotypes of two human NAMPT gene promoter SNPs [-1001T>G and -1535C>T (originally labeled as -1543C>T)] in Caucasian septic patients and Caucasian healthy subjects. We found that the frequency of the minor G allele of the SNP -1001T>G was significantly higher (23%) in septic patients than in healthy subjects (12%, p=0.01). Similarly, the frequency of its genotype GT was significantly higher (44%) in septic patients than in healthy subjects (20%, p=0.004). The haplotype-weighted analysis of these two SNPs indicated that a susceptible haplotype GC had a 4.84-fold higher risk of sepsis while a potential protective haplotype TT had a lowest risk of sepsis in a Caucasian patient population among four haplotypes: GC, GT, TC and TT. Our findings were validated and extended in a different patient cohort by Bajwa et al. . They genotyped the NAMPT T-1001G and C-1543T polymorphisms in 375 patients with ARDS, a frequent consequence of sepsis, and 787 patients at risk for developing ARDS. It was found that among the 397 patients with sepsis syndrome, the odds of developing ARDS were significantly increased by presence of T-1001G and among the 561 patients with septic shock,the odds of developing ARDS for patients with C-1543T were significantly decreased. Overall, the NAMPT T-1001G variant allele and related haplotype are associated with increased odds of developing ARDS and increased hazard of intensive care unit mortality among at-risk patients, whereas the C-1543T variant allele and related haplotype are associated with decreased odds of ARDS among patients with septic shock and better outcomes among patients with ARDS. These results support that NAMPT is a genetic risk factor for sepsis.
4. Molecular Mechanisms of NAMPT in Sepsis
Although the role of NAMPT in sepsis is still incompletely understood, accumulating evidence indicates that at least the following molecular mechanisms may in part underlie NAMPT in sepsis (Figure 2).
Besides sepsis, NAMPT expression is up-regulated in a variety of acute and chronic inflammatory diseases including acute lung injury, inflammatory bowel disease, myocardial infarction, and rheumatoid arthritis. It have been demonstrated
The potent antimicrobial activity by neutrophils is effected through proteolytic enzymes and the generation of reactive oxygen species (ROS). ROS released by neutrophils are also implicated in the bystander tissue injury that accompanies an inflammatory response. Malam et al.  demonstrated that NAMPT can prime neutrophils for increased ROS generation through the NADPH oxidase. NAMPT promoted membrane translocation of cytosolic NADPH oxidase subunits p40 and p47, but not p67, induced p40 phosphorylation on Thr154, and activated the small GTPase Rac. Priming, translocation, and phosphorylation were dependent on activation of p38 and ERK MAPKs, but not of PI3K. Priming by NAMPT occurred independently of its NAD-generating capacity because neither nicotinamide mononucleotide nor NAD could recapitulate the effects, and a specific inhibitor of NAMPT, APO-866, could not inhibit priming. This represents another molecular mechanism underlying NAMPT in the pathogenesis of sepsis, in which increased expression of NAMPT contributes to tissue damage by priming neutrophils to produce excessive ROS.
In a different study, Hong et al.  demonstrated recombinant human NAMPT as a direct rat neutrophil chemotactic factor in in vitro studies. They also demonstrated a marked increase in bronchoalveolar lavage leukocytes after the intratracheal injection of rhNAMPT into C57BL/6J mice in an acute lung injury model. Organ failure is frequently associated with severe sepsis. Chemoattractant property of NAMPT may also in part account for its role of increasing or activating neutrophils in sepsis.
5. Summary and perspective
Increasing evidence suggest that NAMPT is a risk factor in sepsis. NAMPT is highly up-regulated in sepsis and it has been proposed as a diagnostic marker in neonatal sepsis. It was associated with the severity and mortality of patients with sepsis. Genetic epidemiological studies found that a susceptible haplotype GC in the promoter of human NAMPT gene had a 4.84-fold higher risk of sepsis while a potential protective haplotype TT had a lower risk of sepsis in a Caucasian patient population. Those findings indicate that NAMPT is a potential genetic marker in sepsis. A few molecular mechanisms may underlie role of dysregulated NAMPT in the pathogenesis of sepsis. Infection in sepsis can induce the expression of NAMPT gene, which in turn stimulate the expression of other inflammatory cytokines, thus aggravate inflammation in sepsis. Prolonged survival of activated neutrophils by NAMPT via its inhibition of neutrophil apoptosis may be linked to sustained inflammation and the organ injury during sepsis. NAMPT can act as a chemoattractant to neutrophils. Increased expression of NAMPT in sepsis may also contribute to tissue damage by priming neutrophils to produce excessive ROS.
It remains to be fully elucidated that role of NAMPT in sepsis may be a "double-edged sword". Although accumulated evidence as synopsized in this chapter and summarized in the above paragraph indicates that excessive up-regulation of NAMPT expression in sepsis contributes to excessive inflammation and tissue damage in sepsis, emerging evidence also suggests that a modest increase of NAMPT expression in early phase may be of beneficial value. A recent study by Liu et al.  suggested that TLR signaling might increase cellular NAD+ by inducing Nampt expression, which could thereby provide substrate for SIRT1 deacetylase activity. SIRT1 deacetylates RelA/p65 lysine 310 and nucleosomal histone H4 lysine 16 to promote termination of NFκB-dependent transcription, which results in the attenuation of inflammatory response. Thus, Nampt activity promotes endotoxin tolerance.
Therapeutic potential of NAMPT inhibitions to sepsis has not been pursued clinically though several basic and translational studies pointed to the possibility. Jia et al.  demonstrated that the NAMPT antisense oligonucleotide prevented the LPS or other inflammatory cytokines' induced neutrophil apoptosis. In neutrophils of patients with sepsis, addition of PBEF antisense oligonucleotide resulted in a greater than twofold increase in rates of apoptosis. This study indicated that the antisense oligonucleotide to NAMPT could effectively inhibit PBEF expression. Ye et al.  reported a successful knockdown of NAMPT expression by more than 70% in human pulmonary vascular endothelial cells using three NAMPT stealth siRNAs in combination or individually. Our group also showed that a NAMPT antibody can block the function of NAMPT in a mouse model . Several chemical inhibitors of NAMPT such as FK866 (also called APO866 or WK175, (E)-N-[4-(1-benzoylpiperidin-4-yl) butyl]-3-(pyridin-3-yl)) and related compounds have been tested to inhibit tumor cell growth  and in clinical trials as an anticancer agent . Montecucco et al  recently showed that treatment with FK866 reduced myocardial infarct size, neutrophil infiltration and ROS generation within infarcted hearts in vivo in a mouse model of ischemia and reperfusion. It is of interest to explore the therapeutic potential of all these NAMPT inhibitory reagents to sepsis in the clinical setting.
It is anticipated that further elucidation of the role and mechanisms of NAMPT in sepsis will enhance our understanding of molecular pathogenesis underlying NAMPT in sepsis and lead to the development of the NAMPT based strategy and management of sepsis in the future.
Some cited studies in this chapter were in part supported by NIH grants (R01HL080042 and RO1 HL080042-S1, SQY) as well as the start-up funds of Children's Mercy Hospitals and Clinics, University of Missouri (SQY).
Crit Care Med MM Levy Fink. M. P. Marshall J. C. Abraham E. Angus D. Cook D. Cohen J. Opal S. M. Vincent J. L. Ramsay G. 20 International S. C. C. M. E. S. I. C. M. A. C. C. P. A. T. S. S. I. S. Sepsis Definitions. Conference 2003, 31(4):1250-1256.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992
N Engl J Med Martin G. S. Mannino D. M. Eaton S. Moss M. The epidemiology. of sepsis. in the. United States. from 19. through 200. 2003
Crit Care Med Dombrovskiy V. Y. AA Martin Sunderram. J. Paz H. L. Rapid increase. in hospitalization. mortality rates. for severe. sepsis in. the United. States a. trend analysis. from 19. to 200. 2007
Wunderink RG, Waterer GW: Genetics of sepsis and pneumonia.Curr Opin Crit Care 2003
Clin Perinatol Del Vecchio A. Laforgia N. Capasso M. Iolascon A. Latini G. The role. of molecular. genetics in. the pathogenesis. diagnosis of. neonatal sepsis. 2004
JR, Grimm AA, Imai S: The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem Revollo J. R. AA Grimm Imai. S. The N. A. D. biosynthesis pathway. mediated by. nicotinamide phosphoribosyltransferase. regulates Sir. activity in. mammalian cells. 2004
Mol Cell Biol Samal B. Sun Y. Stearns G. Xie C. Suggs S. Mc Niece I. Cloning characterization of. the c. D. N. A. encoding a. novel human. pre-B-cell colony-enhancing. factor 1994
Science Fukuhara A. Matsuda M. Nishizawa M. Segawa K. Tanaka M. Kishimoto K. Matsuki Y. Murakami M. Ichisaka T. Murakami H. et al. Visfatin a. protein secreted. by visceral. fat that. mimics the. effects of. insulin 2005
Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC: Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004, 113(9):1318-1327.
Am J Respir Crit Care Med Ye S. Q. BA Simon Maloney. J. P. Zambelli-Weiner A. Gao L. Grant A. Easley R. B. Mc Verry B. J. Tuder R. M. Standiford T. et al. Pre-B-cell colony-enhancing. as factor a. potential novel. biomarker in. acute lung. injury 2005
Bajwa EK, Yu CL, Gong MN, Thompson BT, Christiani DC: Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome.Crit Care Med 2007
Zhang LQ, Heruth DP, Ye SQ: Nicotinamide Phosphoribosyltransferase in Human Diseases.J Bioanal Biomed 2011
Circ Res van der Veer E. Nong Z. O’Neil C. Urquhart B. Freeman D. Pickering J. G. Pre-B-cell colony-enhancing. factor regulates. N. A. D+-dependent protein. deacetylase activity. promotes vascular. smooth muscle. cell maturation. 2005
Fukuhara A. Matsuda M. Nishizawa M. Segawa K. Tanaka M. Kishimoto K. Matsuki Y. Murakami M. Ichisaka T. Murakami H. et al. Retraction Science. 2007
Calcif Tissue Int Xie H. Tang S. Y. Luo X. H. Huang J. Cui R. R. Yuan L. Q. Zhou H. D. Wu X. P. Liao E. Y. Insulin-like effects. of visfatin. on human. osteoblasts 2007
J, Samal B, Bryant-Greenwood GD: Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol Ognjanovic S. Bao S. Yamamoto S. Y. Garibay-Tupas J. Samal B. Bryant-Greenwood G. D. Genomic organization. of the. gene coding. for human. pre-B-cell colony. enhancing factor. expression in. human fetal. membranes 2001
Arthritis Rheum Brentano F. Schorr O. Ospelt C. Stanczyk J. Gay R. E. Gay S. Kyburz D. Pre-B cell. colony-enhancing factor/visfatin. a. new marker. of inflammation. in rheumatoid. arthritis with. proinflammatory matrix-degrading activities. 2007
Clin Sci (Lond) Tilg H. Moschen A. R. Role of. adiponectin F/visfatin P. B. E. as regulators of. inflammation involvement. in obesity-associated. diseases 2008
Circulation Dahl T. B. Yndestad A. Skjelland M. Oie E. Dahl A. Michelsen A. Damas J. K. Tunheim S. H. Ueland T. Smith C. et al. Increased expression. of visfatin. in macrophages. of human. unstable carotid. coronary atherosclerosis. possible role. in inflammation. plaque destabilization. 2007
Am J Obstet Gynecol Ognjanovic S. Bryant-Greenwood G. D. Pre-B-cell colony-enhancing. factor a. novel cytokine. of human. fetal membranes. 2002
J, Xia Y, Kempf JA, Ye H, Zhang LQ, Ye SQ: Regulation of inflammatory cytokine expression in pulmonary epithelial cells by pre-B-cell colony-enhancing factor via a nonenzymatic and AP-1-dependent mechanism. J Biol Chem Liu P. Li H. Cepeda J. Xia Y. Kempf J. A. Ye H. Zhang L. Q. Ye S. Q. Regulation of. inflammatory cytokine. expression in. pulmonary epithelial. cells by. pre-B-cell colony-enhancing. factor via. a. nonenzymatic P- 1-dependent A. mechanism 2009
J, Fang D, Easley RB, Simon BA, Zhang LQ, Ye SQ: Augmentation of Pulmonary Epithelial Cell IL-8 Expression and Permeability by Pre-B-cell Colony Enhancing Factor. J Inflamm (Lond) Li H. Liu P. Cepeda J. Fang D. Easley R. B. BA Simon Zhang. L. Q. Ye S. Q. Augmentation of. Pulmonary Epithelial. Cell I. L. Expression Permeability by. Pre-B-cell Colony. Enhancing Factor. 2008
Am J Respir Crit Care Med Hong S. B. Huang Y. Moreno-Vinasco L. Sammani S. Moitra J. Barnard J. W. Ma Mirzapoiazova S. F. Evenoski T. Reeves C. et R. R. al Essential. role of. pre-B-cell colony. enhancing factor. in ventilator-induced. lung injury. 2008
Martin PR, Shea RJ, Mulks MH: Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol 2001
Eur J Immunol Rongvaux A. Shea R. J. Mulks M. H. Gigot D. Urbain J. Leo O. Andris F. Pre-B-cell colony-enhancing. factor whose. expression is. up-regulated in. activated lymphocytes. is a. nicotinamide phosphoribosyltransferase. a. cytosolic enzyme. involved in. N. A. D. biosynthesis 2002
JG: Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem van der Veer E. Ho C. O’Neil C. Barbosa N. Scott R. Cregan S. P. Pickering J. G. Extension of. human cell. lifespan by. nicotinamide phosphoribosyltransferase. 2007
Trends Biochem Sci Berger F. Ramirez-Hernandez M. H. Ziegler M. The new. life of. a. centenarian signalling. functions of. N. A. D. P. 2004
Emerging roles of NAD in cellular signaling. Eur J Biochem Ziegler M. New functions. of a. long-known molecule. 2000
EMBO J Yeung F. Hoberg J. E. Ramsey C. S. MD Keller Jones. D. R. Frye R. A. Mayo M. W. Modulation of. N. F-kappa B-dependent. transcription cell survival. by the. S. I. R. T. deacetylase E. M. B. 2004
EMBO J Corda D. Di Girolamo M. Functional aspects. of protein. mono-A D. P-ribosylation E. M. B. 2003
Biochem J Gerth A. Nieber K. Oppenheimer N. J. Hauschildt S. Extracellular N. A. D. regulates intracellular. free calcium. concentration in. human monocytes. 2004Pt 3):849-856.
Intyre JP, Pope BL: The involvement of protein kinase C, calcium, and 5-lipoxygenase in the production of tumor necrosis factor by a cloned interleukin-3 dependent cell line with natural cytotoxic activity. Int J Immunopharmacol Mac Intyre. J. P. Pope B. L. The involvement. of protein. kinase C. calcium 5-lipoxygenase in. the production. of tumor. necrosis factor. by a. cloned interleukin. dependent cell. line with. natural cytotoxic. activity 1991
Nadra I. Mason J. C. Philippidis P. Florey O. Smythe C. D. Mc Carthy G. M. Landis R. C. DO Haskard Proinflammatory. activation of. macrophages by. basic calcium. phosphate crystals. via protein. kinase C. kinase M. A. P. pathways a. vicious cycle. of inflammation. arterial calcification?. Circ Res. 2005
Lee KA, Gong MN: Pre-B-cell colony-enhancing factor and its clinical correlates with acute lung injury and sepsis.Chest 2011
Eur Cytokine Netw Cekmez F. Canpolat F. E. Cetinkaya M. Aydinoz S. Aydemir G. Karademir F. Ipcioglu O. M. Sarici S. U. Diagnostic value. of resistin. visfatin in. comparison with. C-reactive protein. procalcitonin interleukin in neonatal. sepsis 2011
Mediators Inflamm Cai B. Deitch E. A. Ulloa L. Novel insights. for systemic. inflammation in. sepsis hemorrhage 2010
Cell Biol Int Liu P. Li H. Cepeda J. Zhang L. Q. Cui X. Garcia J. G. Ye S. Q. Critical role. of P. B. E. F. expression in. pulmonary cell. inflammation permeability 2009
Smith J. A. Neutrophils host. defense inflammation a. double-edged sword. J. Leukoc Biol. 1994
Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF: Neutrophils in development of multiple organ failure in sepsis.Lancet 2006
J, Waheed F, Szaszi K, Kapus A, Marshall JC: Pre-B cell colony-enhancing factor (PBEF/Nampt/visfatin) primes neutrophils for augmented respiratory burst activity through partial assembly of the NADPH oxidase. J Immunol Malam Z. Parodo J. Waheed F. Szaszi K. Kapus A. Marshall J. C. Pre-B cell. colony-enhancing factor. . P. B. E. F. Nampt/visfatin primes. neutrophils for. augmented respiratory. burst activity. through partial. assembly of. the N. A. D. P. H. oxidase 2011
J Biol Chem Liu T. F. Yoza B. K. El Gazzar M. Vachharajani V. T. CE Mc Call N. A. D+-dependent S. I. R. T. deacetylase participates. in epigenetic. reprogramming during. endotoxin tolerance. 2011
Cancer Res Hasmann M. Schemainda I. F. K86 highly a. specific noncompetitive. inhibitor of. nicotinamide phosphoribosyltransferase. represents a. novel mechanism. for induction. of tumor. cell apoptosis. 2003
Invest New Drugs Holen K. Saltz L. B. Hollywood E. Burk K. Hanauske A. R. The pharmacokinetics. toxicities biologic effects. of F. K86 nicotinamide a. adenine dinucleotide. biosynthesis inhibitor. 2008
Antioxid Redox Signal Montecucco F. Bauer I. Braunersreuther V. Bruzzone S. Akhmedov A. Luscher T. F. Speer T. Poggi A. Mannino E. Pelli G. et al. Inhibition of. nicotinamide phosphoribosyltransferase. . Nampt reduces. neutrophil-mediated injury. in myocardial. infarction 2012